{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:20:58Z","timestamp":1791980458953,"version":"4.4.0"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ejca.2025.115595","type":"journal-article","created":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T17:18:08Z","timestamp":1751563088000},"page":"115595","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2619-5945","authenticated-orcid":false,"given":"Daniela","family":"Scattolin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6105-182X","authenticated-orcid":false,"given":"Anne-Marie C.","family":"Dingemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Dal Maso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2375-8397","authenticated-orcid":false,"given":"Valentina","family":"Guarneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim G.J.V.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pasello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5578-7902","authenticated-orcid":false,"given":"Daphne W.","family":"Dumoulin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2025.115595_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Prim"},{"issue":"1","key":"10.1016\/j.ejca.2025.115595_bib2","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1097\/COC.0b013e31828aab2a","article-title":"Outcomes of small cell lung cancer patients treated with cisplatin-etoposide versus carboplatin-etoposide","volume":"38","author":"Karam","year":"2015","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115595_bib3","article-title":"Immunotherapy for extensive-stage small-cell lung cancer: current landscape and future perspectives","volume":"13","author":"Zhang","year":"2023","journal-title":"Front Oncol"},{"key":"10.1016\/j.ejca.2025.115595_bib4","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.lungcan.2023.02.003","article-title":"Efficacy and safety of first-line immune checkpoint inhibitors combined with chemotherapy for extensive-stage small cell lung cancer: A network meta-analysis","volume":"178","author":"Wang","year":"2023","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2025.115595_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2024.107924","article-title":"Five-year survival in patients with extensive-stage small cell lung cancer treated with atezolizumab in the Phase III IMpower133 study and the Phase III IMbrella A extension study","volume":"196","author":"Reck","year":"2024","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2025.115595_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100408","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN","volume":"7","author":"Paz-Ares","year":"2022","journal-title":"ESMO Open"},{"issue":"7","key":"10.1016\/j.ejca.2025.115595_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","article-title":"Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2606","volume":"32","author":"Dingemans","year":"2021","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ejca.2025.115595_bib8","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2025.115595_bib9","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.annonc.2023.10.001","article-title":"ESMO Guidance for Reporting Oncology real-World evidence (GROW)","volume":"34","author":"Castelo-Branco","year":"2023","journal-title":"Ann Oncol J Eur Soc Med Oncol"},{"key":"10.1016\/j.ejca.2025.115595_bib10","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ejca.2022.06.020","article-title":"Lurbinectedin shows clinical activity and immune-modulatory functions in patients with pre-treated small cell lung cancer and malignant pleural mesothelioma","volume":"172","author":"Dumoulin","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2025.115595_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.112985","article-title":"Trends in the epidemiology of small-cell lung cancer: a Dutch nationwide population-based study over 1989-2020","volume":"191","author":"Dumoulin","year":"2023","journal-title":"Eur J Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2025.115595_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2024.103968","article-title":"Lurbinectedin in extensive-stage small-cell lung cancer: a brief report of the IFCT-2105 LURBICLIN study","volume":"9","author":"Girard","year":"2024","journal-title":"ESMO Open"},{"issue":"8","key":"10.1016\/j.ejca.2025.115595_bib13","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.cllc.2023.09.001","article-title":"Real-World Outcomes With Lurbinectedin in Second-Line Setting and Beyond for Extensive Stage Small Cell Lung Cancer","volume":"24","author":"Desai","year":"2023","journal-title":"Clin Lung Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2025.115595_bib14","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1111\/imj.16348","article-title":"Lurbinectedin in small cell lung cancer: real-world experience of a multicentre national early access programme","volume":"54","author":"Alexander","year":"2024","journal-title":"Intern Med J"},{"issue":"13","key":"10.1016\/j.ejca.2025.115595_bib15","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1080\/14796694.2025.2499441","article-title":"Real-world use, effectiveness, and safety of second-line lurbinectedin monotherapy in small cell lung cancer","volume":"21","author":"Ganti","year":"2025","journal-title":"Future Oncol"},{"key":"10.1016\/j.ejca.2025.115595_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/srep15437","article-title":"Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 Patients","volume":"5","author":"Horita","year":"2015","journal-title":"Sci Rep"},{"issue":"25","key":"10.1016\/j.ejca.2025.115595_bib17","article-title":"Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial","volume":"S0140-6736","author":"Paz-Ares","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2025.115595_bib18","unstructured":"US Food and Drug Administration (FDA). FDA grants accelerated approval to tarlatamab-dlle for extensive stage small cell lung cancer. FDA;2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-tarlatamab-dlle-extensive-stage-small-cell-lung-cancer."}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T08:05:03Z","timestamp":1791360303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925003776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":18,"alternative-id":["S0959804925003776"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115595","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome and safety of lurbinectedin as compassionate use in extensive stage small cell lung cancer: A multicentric international cohort","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115595","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115595"}}